ClinicalTrials.gg
CompletedNCT01291511REPRIEVEUpdated Jul 17, 2023Results posted

Relapse Prevention Study in Patients With Schizophrenia

A Phase 3 interventional study of Iloperidone and Placebo in Schizophrenia, sponsored by Vanda Pharmaceuticals. Completed at 63 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-17.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
635
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.

Enrollment
Largest of 11
635 · median 260
Started
2011
with 1 other
Phase 3
4 of 11
1 open now
Registered
3rd of 11
by date
Lead sponsor
7 of 11
Vanda Pharmaceuticals

Among the 11 studies testing iloperidone in Schizophrenia, this one has the largest enrollment, is one of 2 that started in 2011, is one of 4 in phase 3, and was the 3rd registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About iloperidone

iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing iloperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia

03

Conditions studied

  • Schizophrenia

Keywords

  • Schizophrenia
  • Mental Disorders
  • Antipsychotic Agents
  • Iloperidone
  • Relapse Prevention
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients must understand and be capable to communicate adequately with the study coordinator and to participate in cognitive testing.
  • Patients must agree to cooperate with all tests and examinations required by the protocol, be willing to comply fully with treatment and able to ingest oral medication.
  • Patients must understand the nature of the study and must sign an document.
  • Patients will have a clear diagnosis of schizophrenia according to criteria for at least 1 year.
  • Patients must need of ongoing psychiatric treatment and must have a documented reason why a change in treatment is needed which might lead to a clinical improvement
  • At screening patients will have a Positive and Negative Syndrome Scale (PANSS) of no more than 100 and a Clinical Global Impression Scale (CGI) of no more than 5 (i.e. must not be severely ill or worse).
  • Patients must be outpatients at the time of screening and have not been an inpatient to treat schizophrenia for at least 1 week prior to the screening visit.
  • Patients must have a history of at least 2 prior episodes of relapse or impending relapse in the 2 years preceding the screening visit.

Exclusion Criteria:-

  • Pregnant or nursing (lactating) women, or women who plan on conceiving during the course of the study.
  • Patients who meet the DSM-IV criteria for schizophreniform disorder (295.40) and schizoaffective (295.70).
  • Patients with active symptoms of any other primary psychiatric diagnosis (Axis I) or prominent Axis II disorder which would interfere with compliance to the protocol.
  • Patients who have a diagnosis or history suggestive of chemical dependence, or drug-induced toxic psychosis in the preceding 6 months; diagnosis or history of abuse (except for nicotine and caffeine) within the past 3 months, or a clinical presentation possibly confounded by the use of recreational drugs or alcohol.
  • Patients who have a positive urine drug screen (at the screening visit). If opiates are positive at screening and clearly due to the use of pain killing medication, the patient may be re screened after the medication has been discontinued and enrolled in the study if urine drug screen is negative.
  • Note: Occasional users of recreational drugs other than cocaine, amphetamines, hallucinogens, or parenteral drugs may be recruited. Patients who are dependent on nicotine, caffeine, or theophylline are allowed to enter the study.
  • Patients who are mentally disabled (moderate to severe).
  • Patients who have had a history of being in a coma for more than 24 hrs.
  • Patients who have had thoughts of committing suicide within 6 months prior to screening or at baseline or suicide behaviors within 2 years prior to screening or at baseline.
  • Patients thought to be of imminent risk of harm to others or in imminent legal difficulty.
  • Patients under any form of legal compulsion to remain hospitalized or undergo treatment or assessment.
  • Patients who have any disability that prevent them from completing any of the study requirements.
  • Patients with a known abnormality including PR interval >240 msec, QRS complex >110 msec, >=450 msec, or congenital long QT syndrome based on central ECG reading results
  • Treatment naive, first episode patients,
  • Patients taking iloperidone at the screening visit or with a known to drugs chemically related to benzioxazoles.
  • Note: Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the patient or the study results.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
635 participants (actual)

Study arms

  • Experimental
    Iloperidone

    After meeting all entry criteria, completing a 1-week open-label iloperidone titation period (up to 12 mg/day), followed by a 14-24 week open-label iloperidone flexible dose-stabilization period (up to 24 mg/day), approximately 260 patients will be randomized to one of two arms in a 1:1 ratio of iloperidone (flexible dosing 8-24 mg/day) to placebo. Post-randomization double-blind study medication will be administered orally twice daily for up to 26 weeks to evaluate relapse prevention. Subsequently, during the extension period, after a 1-week mock double-blind titration, open-label iloperidone (8-24 mg/day) is administered for up to 51 weeks to evaluate long-term safety.

    Drug: Iloperidone

  • Placebo comparator
    Placebo

    Post-randomization matching placebo is administered orally bid during the double-blind period.

    Drug: Placebo

Interventions

  • Over-encapsulated iloperidone tablets were administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.

    Also known as: Fanapt®

  • DrugPlacebo

    Matching placebo capsules were administered orally using a bid schedule during the double-blind period.

06

What researchers measure

Primary outcomes

  1. Time to Relapse or Impending Relapse

    Relapse or impending relapse was defined as any of the following: hospitalization due to worsening of schizophrenia; increase (worsening) of the PANSS total score of greater than or equal to 30% from randomization, PANSS total score confirmed at a second visit conducted within 1-7 days; clinically significant emergent or worsening suicidal, homicidal, or aggressive behavior; a CGI-Improvement (CGI-I) score of 6 (much worse) or 7 (very much worse) after randomization; a dose increase in study medication or a need for additional open-label antipsychotic treatment.

    Time frame: Up to 26 weeks post-randomization

Secondary outcomes

  1. PANSS Total Score, Change From Baseline to Last Visit

    The 30-item Positive and Negative Syndrome Scale (PANSS) was developed to assess the severity of symptoms of schizophrenia. The PANSS items are divided into positive, negative, and general psychopathology factors. All items were rated on a scale of 1 (absent) to 7 (extremely severe). The PANSS total score (or rating) is the sum of all 30 PANSS items taken together (the sum of its 3 subscales), with a maximum score of 210. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.

    Time frame: Up to 26 weeks post-randomization

  2. CGI-S, Last Visit

    The 7-item Clinical Global Impression of Severity (CGI-S) scale was developed to assess the overall, absolute degree of illness at any point in time. A rating of 1 is equivalent to "normal, not at all ill," and a rating of 7 is equivalent to "among the most extremely ill patients."

    Time frame: Up to 26 weeks post-randomization

  3. SDS Total Score, Change From Baseline to Last Visit

    The Sheehan Disability Scale (SDS) a self-reported measure that was developed to assess functional impairment in 3 inter-related domains (i.e., work/school, social, and family life). It is a 10-point visual analog scale with 0 being not impaired at all and 10 extremely impaired. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.

    Time frame: Up to 26 weeks post-randomization

07

Results

Posted Jul 17, 2023
Limitations and caveats
The primary limitation of the study design is that the length of the placebo-controlled phase of the study lasted for only 6 months. However, ethical considerations around the use of placebo in this patient population necessarily informed the study design. While the flexible-dosing regimen in this study allowed for a more real-world experience, it also prevented the assessment of dose-response.

Participant flow

Cross-Titration and Stabilization Phase
Participant flow — Cross-Titration and Stabilization Phase
MilestoneIloperidonePlacebo
Started6350
Completed3090
Not completed3260
Withdrew: Withdrawal by subject1070
Withdrew: Adverse event920
Withdrew: Administrative problems300
Withdrew: Lack of efficacy280
Withdrew: Abnormal laboratory value250
Withdrew: Lost to follow-up240
Withdrew: Protocol violation130
Withdrew: Abnormal test60
Withdrew: Death10
Double-blind Relapse Prevention Phase
Participant flow — Double-blind Relapse Prevention Phase
MilestoneIloperidonePlacebo
Started153150
Completed76102
Not completed7748
Withdrew: Administrative problems4529
Withdrew: Withdrawal by subject1410
Withdrew: Lost to follow-up64
Withdrew: Adverse event50
Withdrew: Abnormal laboratory value42
Withdrew: Protocol violation11
Withdrew: Lack of efficacy02
Withdrew: Abnormal test10
Withdrew: Death10

Outcome measures

PrimaryTime to Relapse or Impending Relapse

Relapse or impending relapse was defined as any of the following: hospitalization due to worsening of schizophrenia; increase (worsening) of the PANSS total score of greater than or equal to 30% from randomization, PANSS total score confirmed at a second visit conducted within 1-7 days; clinically significant emergent or worsening suicidal, homicidal, or aggressive behavior; a CGI-Improvement (CGI-I) score of 6 (much worse) or 7 (very much worse) after randomization; a dose increase in study medication or a need for additional open-label antipsychotic treatment.

Time frame:
Up to 26 weeks post-randomization
Reported as:
Median · Days
Time to Relapse or Impending Relapse
DaysIloperidonePlacebo
Time to Relapse or Impending RelapseNA (NA to NA)99 (57 to 122)
Statistical analysis
  • Iloperidone vs Placebo · Log Rank · p = <0.0001 · Cox proportional hazard: 5.2 · 95% CI 3.2 to 8.4
SecondaryPANSS Total Score, Change From Baseline to Last Visit

The 30-item Positive and Negative Syndrome Scale (PANSS) was developed to assess the severity of symptoms of schizophrenia. The PANSS items are divided into positive, negative, and general psychopathology factors. All items were rated on a scale of 1 (absent) to 7 (extremely severe). The PANSS total score (or rating) is the sum of all 30 PANSS items taken together (the sum of its 3 subscales), with a maximum score of 210. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.

Time frame:
Up to 26 weeks post-randomization
Reported as:
Mean · units on a scale
PANSS Total Score, Change From Baseline to Last Visit
units on a scaleIloperidonePlacebo
PANSS Total Score, Change From Baseline to Last Visit1.1 ± 1.1212.4 ± 1.15
Statistical analysis
  • Iloperidone vs Placebo · ANCOVA · p = <0.0001 (P-value is based on an ANCOVA model with treatment and site as main effects and DBRP baseline as a covariate.)
SecondaryCGI-S, Last Visit

The 7-item Clinical Global Impression of Severity (CGI-S) scale was developed to assess the overall, absolute degree of illness at any point in time. A rating of 1 is equivalent to "normal, not at all ill," and a rating of 7 is equivalent to "among the most extremely ill patients."

Time frame:
Up to 26 weeks post-randomization
Reported as:
Mean · units on a scale
CGI-S, Last Visit
units on a scaleIloperidonePlacebo
CGI-S, Last Visit3.0 ± 0.893.6 ± 1.11
SecondarySDS Total Score, Change From Baseline to Last Visit

The Sheehan Disability Scale (SDS) a self-reported measure that was developed to assess functional impairment in 3 inter-related domains (i.e., work/school, social, and family life). It is a 10-point visual analog scale with 0 being not impaired at all and 10 extremely impaired. Change from baseline is calculated as post value minus baseline value. A negative change indicates improvement.

Time frame:
Up to 26 weeks post-randomization
Reported as:
Mean · units on a scale
SDS Total Score, Change From Baseline to Last Visit
units on a scaleIloperidonePlacebo
SDS Total Score, Change From Baseline to Last Visit-0.2 ± 0.541.8 ± 0.61
Statistical analysis
  • Iloperidone vs Placebo · ANCOVA · p = 0.0062 (P-value is based on an ANCOVA model with treatment and site as main effects and DBRP baseline as a covariate.)

Adverse events

Collected over Cross-Titration Phase (1 week) and Stabilization Phase (14-24 weeks); Relapse-prevention phase (up to 26 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Iloperidone (Cross-titration and Stabilization Phase)1/629 (0.2%)21/629 (3.3%)244/629 (38.8%)
Iloperidone (Relapse-prevention Phase)1/151 (0.7%)6/151 (4%)16/151 (10.6%)
Placebo (Relapse-prevention Phase)0/150 (0%)4/150 (2.7%)30/150 (20%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventIloperidone (Cross-titration and Stabilization Phase)Iloperidone (Relapse-prevention Phase)Placebo (Relapse-prevention Phase)
SchizophreniaPsychiatric disorders9/6292/1512/150
Acute psychosisPsychiatric disorders0/6290/1511/150
Suicidal ideationPsychiatric disorders1/6290/1511/150
ArrhythmiaCardiac disorders0/6291/1510/150
Femoral neck fractureInjury, poisoning and procedural complications0/6291/1510/150
HypernatraemiaMetabolism and nutrition disorders0/6291/1510/150
HyponatraemiaMetabolism and nutrition disorders0/6291/1510/150
ConvulsionNervous system disorders0/6291/1510/150
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/6291/1510/150
Hepatitis acuteHepatobiliary disorders1/6290/1510/150
Most frequent other events
Most frequent other events
EventIloperidone (Cross-titration and Stabilization Phase)Iloperidone (Relapse-prevention Phase)Placebo (Relapse-prevention Phase)
DizzinessNervous system disorders73/6294/1514/150
SchizophreniaPsychiatric disorders8/6291/15113/150
SomnolenceNervous system disorders52/6292/1510/150
Dry mouthGastrointestinal disorders43/6290/1510/150
HeadacheNervous system disorders40/6293/1515/150
InsomniaPsychiatric disorders35/6293/1517/150
Weight IncreasedInvestigations34/6292/1514/150
NauseaGastrointestinal disorders32/6292/1510/150

Baseline characteristics

Age, Continuous
Age, Continuous(years)IloperidonePlaceboTotal
Mean38.4 ± 11.338.2 ± 11.138.3 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)IloperidonePlaceboTotal
Female5768125
Male9682178
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IloperidonePlaceboTotal
Caucasian7477151
Black312859
Asian384078
Pacific Islander101
Other9514
08

Study locations

63 sites
  • Vanda Investigative Site
    Anaheim, California 92604, United States
  • Vanda Investigative Site
    Bellflower, California 92706, United States
  • Vanda Investigative Site
    Costa Mesa, California 92626, United States
  • Vanda Investigative Site
    Escondido, California 92025, United States
  • Vanda Investigative Site
    La Habra, California 90631, United States
  • Vanda Investigative Site
    Oceanside, California 92056, United States
  • Vanda Investigative Site
    Orange, California 92868, United States
  • Vanda Investigative Site
    Pico Rivera, California 90660, United States
  • Vanda Investigative Site
    Riverside, California 92506, United States
  • Vanda Investigative Site
    San Diego, California 92102, United States
  • Vanda Investigative Site
    San Diego, California 92103, United States
  • Vanda Investigative Site
    San Diego, California 92121, United States
  • Vanda Investigative Site
    Santa Ana, California 92705, United States
  • Vanda Investigative Site
    Melbourne, Florida 32901, United States
  • Vanda Investigative Site
    Miami, Florida 33126, United States
  • Vanda Investigative Site
    Oakland Park, Florida 33334, United States
  • Vanda Investigative Site
    Atlanta, Georgia 30308, United States
  • Vanda Investigative Site
    Atlanta, Georgia 30328, United States
  • Vanda Investigative Site
    Saint Louis, Missouri 63109, United States
  • Vanda Investigative Site
    Nashua, New Hampshire 03060, United States
  • Vanda Investigative Site
    Marlton, New Jersey 08053, United States
  • Vanda Investigative Site
    Brooklyn, New York 11235, United States
  • Vanda Investigative Site
    Staten Island, New York 10312, United States
  • Vanda Investigative Site
    Hickory, North Carolina 28601, United States
  • Vanda Investigative Site
    Beachwood, Ohio 44122, United States
  • Vanda Investigative Site
    Philadelphia, Pennsylvania 19139, United States
  • Vanda Investigative Site
    Irving, Texas 75062, United States
  • Vanda Investigative Site
    Salt Lake City, Utah 84106, United States
  • Vanda Investigative Site
    Ahmedabad, Gujarat 380013, India
  • Vanda Investigative Site
    Madhava Nagar, Karnataka 576104, India
  • Vanda Investigative Site
    Mangalore, Karnataka 575001, India
  • Vanda Investigative Site
    Mangalore, Karnataka 575018, India
  • Vanda Investigative Site
    Mysore, Karnataka 570004, India
  • Vanda Investigative Site
    Nashik, Maharashtra 422101, India
  • Vanda Investigative Site
    Pune, Maharashtra 411030, India
  • Vanda Investigative Site
    Jaipur, Rajasthan 302021, India
  • Vanda Investigative Site
    Madurai, Tamilnadu 625020, India
  • Vanda Investigative Site
    Kanpur, Uttar Pradesh 208005, India
  • Vanda Investigative Site
    Lucknow, Uttar Pradesh 226003, India
  • Vanda Investigative Site
    Lucknow, Uttar Pradesh 226006, India
  • Vanda Investigative Site
    Varanasi, Uttar Pradesh 221005, India
  • Vanda Investigative Site
    Kerch, AR Crimea 98310, Ukraine
  • Vanda Investigative Site
    Yevpatoriya, AR Crimea 97416, Ukraine
  • Vanda Investigative Site
    Chernihiv, 14000, Ukraine
  • Vanda Investigative Site
    Dnipropetrovsk, 49005, Ukraine
  • Vanda Investigative Site
    Dnipropetrovsk, 49115, Ukraine
  • Vanda Investigative Site
    Donetsk, 83037, Ukraine
  • Vanda Investigative Site
    Donezk, 83008, Ukraine
  • Vanda Investigative Site
    Ivano-Frankivsk, 76014, Ukraine
  • Vanda Investigative Site
    Kharkiv, 61068, Ukraine
  • Vanda Investigive Site
    Kharkiv, 68061, Ukraine
  • Vanda Investigative Site
    Kyiv, 01030, Ukraine
  • Vanda Investigative Site
    Kyiv, 02660, Ukraine
  • Vanda Investigative Site
    Kyiv, 04080, Ukraine
  • Vanda Investigative Site
    Kyiv, 08631, Ukraine
  • Vanda Investigative Site
    Lugansk, 91045, Ukraine
  • Vanda Investigative Site
    Odesa, 65014, Ukraine
  • Vanda Investigative Site
    Poltava, 36006, Ukraine
  • Vanda Investigative Site
    Simferopol, 95006, Ukraine
  • Vanda Investigative Site
    Stepanivka, 73488, Ukraine
  • Vanda Investigative Site
    Ternopil, 46020, Ukraine
  • Vanda Investigative Site
    Uzhgorod, 88000, Ukraine
  • Vanda Investigative Site
    Vinnytsya, 21005, Ukraine
09

References and documents

Publications

  • Weiden PJ, Manning R, Wolfgang CD, Ryan JM, Mancione L, Han G, Ahmed S, Mayo MG. A Randomized Trial of Iloperidone for Prevention of Relapse in Schizophrenia: The REPRIEVE Study. CNS Drugs. 2016 Aug;30(8):735-47. doi: 10.1007/s40263-016-0345-4. PubMed 27379654 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2011 to primary completion in Mar 2014, 37 months.

Results were first posted in Jul 2023, 9 years 4 months after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 37 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2011
First posted
Feb 8, 2011
StartActual
Feb 2011
Primary completionActual
Mar 2014
CompletionActual
Mar 2015
Results first posted
Jul 17, 2023
Last update
Jul 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01291511
Responsible party
Sponsor
First posted
Feb 8, 2011
Start date
Feb 2011
Primary completion
Mar 2014
Completion
Mar 2015
Results posted
Jul 17, 2023
Last update
Jul 17, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iloperidone

Start the discussion